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Is MB Creatine Kinase the Choice for the 1990s?
Jesse E. Adams III, MD; Dana R. Abendschein, PhD; Allan S. Jaffe, MD M odern medical practice requires rapid decisions. Patients must be triaged faster, treated more expeditiously, and discharged earlier. Diagnostic tests used to evaluate patients with possible myocardial ischemia/infarction must be simple to perform and must rapidly and accurately accomplish several goals: (1) Differentiate patients with and without acute myocardial infarction (AMI). Only a small percentage (10% to 20%) of patients with chest discomfort or other symptoms compatible with ischemia have infarction.1 There is enthusiasm for the concept that molecular markers might be able to define this group rapidly enough to aid in deciding which patients should receive treatment with thrombolytic agents and which patients are at sufficiently low risk that they could be sent home or cared for in a less intensive and thus less costly facility than an intensive care unit. (2) Distinguish patients who have coronary recanalization after treatment with thrombolytic agents from those who do not so that those in need of additional treatment can be identified. (3) Permit estimation of the extent of myocardial damage, the most reliable predictor of survival after acute myocardial infarction. 2 Although tests for the MB isoenzyme of creatine kinase (CK) in plasma have served all of these purposes for nearly three decades, increases in MBCK are not as specific for myocardial injury as first believed and occur too late for optimal early diagnosis of infarction or prompt detection of coronary recanalization. In addition, the complex kinetics of release and clearance after reperfusion confound analyses of infarct size. Because of these limitations, alternative markers have been investigated. Are they better, or will these markers have similar or even more significant limitations than MBCK?
Historical Perspective The report of Karmen et al in 19543 that serum glutamate oxaloacetate transaminase (SGOT, now aspartate transaminase or AST) activity was increased in the serum of patients with AMI stimulated an explosion in diagnostic testing. Because of greater specificity for heart, measurement of lactate dehydrogenase (now designated LD) and then LD isoenzymes replaced AST for the confirmation of myocardial injury. 4 However, the rapid appearance of CK in serum after AMI5 and the improved specificity for myocardial injury provided by measurement of the MB isoenzyme6 quickly established MBCK as the marker of choice. Nevertheless, it became clear that the ECG could be normal despite biochemical evidence of myocardial damage7 and that marked ECG changes could occur without increased concentrations of cardiac proteins in the blood.8 Thus, the current World Health Organization criteria for the diagnosis of AMI includes the presence of two of the following criteria: clinical symptoms compatible with acute ischemia, ECG abnormalities, and a pattern of enzyme release typical of myocardial injury. It has been suggested that a typical rising and falling pattern of MBCK alone in the proper clinical setting should suffice for confirmation of AMI.9 Characteristics of Markers of Myocardial Injury An ideal marker of myocardial injury would (1) be found in high concentration in myocardium, (2) not be found in other tissues, even in trace amounts or under pathological conditions, (3) be released rapidly and completely after myocardial injury, (4) be released in direct proportion to the extent of myocardial injury, and (5) persist in plasma for several hours to provide a convenient diagnostic time window but not so long that recurrent injury would not be identified.
Determining Factors
The factors that determine these characteristics and the sensitivity and specificity of each marker are size, cellular localization, solubility, release ratio, clearance, specificity for myocardium, specificity for irreversible injury, and detectability.
Size. In general, the smaller the molecular marker, the more rapidly it is released into the circulation. 10 Thus, levels of low molecular weight markers such as myoglobin are likely to be elevated earlier than higher molecular weight markers such as LD4 and CK."1 Cellular localization. Cytosolic proteins are released more rapidly than are structural proteins after damage to the sarcolemma, resulting in earlier plasma elevations. 12 Solubility. Macromolecules of low solubility, including some cardiac contractile proteins, move slowly out of the myocardium.
Release ratio. Some macromolecules, eg, CK, may undergo local degradation after release.13,4 Thus, the amount of marker depleted from the heart may be substantially greater than the amount that can be measured in plasma. The release ratio is rarely 1; some protein usually remains within the central region of infarction where blood flow is the lowest.'5 Changes in blood flow may alter the release ratio; eg, reperfusion markedly increases the amount of CK depleted from heart that appears in plasma. 16 Clearance. Smaller markers generally are cleared more rapidly than those of greater size.10'11 Thus, markers with shorter plasma half-lives are better for characterizing the timing of events such as reperfusion or reinfarction if frequent blood samples can be obtained. 17 Markers with longer half-lives are better for integrating events over time with infrequent samples but often will be insensitive to new release, eg, from recurrent myocardial injury. In addition, a marker's clearance is a critical determinant of detectability (see below).
Specificity for myocardium. Most macromolecules in the heart also are abundant in skeletal muscle, especially under pathological conditions. After injury, cells alter the molecular species they produce, recapitulating production of proteins produced in utero or early in life (a "return to ontogeny"'). [18] [19] [20] [21] Specificity for irreversible injury. It is controversial whether the release of cytosolic proteins indicates cell death. Although the sarcolemma must be damaged for release to occur, it is not clear whether the damage must be so extensive that the cell is irreversibly injured.22-25 Specificity for irreversible injury has been difficult to define because of limitations in the detectability of marker proteins in plasma, which is related to the plasma levels normally present and the sensitivity of the assay, and because of limitations in the morphological detection of myocardial necrosis. Release of small amounts of proteins could be undetectable after reversible ischemia if baseline levels are too variable, if assays are not sufficiently sensitive, or if the increment in the plasma level does not exceed the upper bound of the physiological range of the marker, leading to the erroneous conclusion that only irreversible injury causes enzyme release. Conversely, if the release ratio is high or levels of the marker in plasma are low and thus detectability high, protein levels in plasma rather than morphological assessment may be more sensitive for the detection of myocardial necrosis, especially if areas of cell death are not contiguous. The majority of the evidence supports the latter hypothesis, in our view. Prolonged release of structural proteins should be highly specific for irreversible injury.
Detectability. In addition to the issues noted above, detectability requires accurate and easy-to-use assays with high sensitivity and low variability. In general, markers that under normal circumstances are present in very low levels in plasma provide the best diagnostic accuracy. The assumption that detection of markers by different assays is equally precise or that the results of activity and mass assays are equivalent is not necessarily valid. 26 The above considerations must be understood in their clinical context. The accuracy of diagnosis and especially the specificity of any test are dependent in large part on the patient population to which they are applied. Thus, increases in the levels of molecular markers of cardiac injury have better specificity for the diagnosis of AMI when symptoms characteristic of ischemia are present. Conversely, improved analytic sensitivity may
The following review summarizes what is known about several conventional and some new molecular markers of myocardial injury to provide a structure within which to consider the biological and clinical importance of markers available in the 1990s. It also summarizes the practical applications of molecular markers for the diagnosis of AMI, for early detection of infarction, for detection of coronary artery recanalization after treatment with thrombolytic agents, and for estimation of infarct size. Finally, it provides a discussion of possible changes in the use of these markers during the 1990s.
The markers to be considered are CK isoenzymes, CK isoforms, myoglobin, myosin fragments, LD, troponins, heart fatty acid binding protein, and enolase. Their characteristics are detailed in Table 1 
Specificity of CKfor Irreversible Injury
In most studies, release of MBCK into plasma correlates with other evidence of myocardial injury. In addition, increases in MBCK do not occur after ischemia evoked by stress testing8 or in most patients with severe unstable angina.45'46 However, in some experimental studies, small amounts of MBCK have been detected in lymph, coronary sinus effluent, and plasma in the absence of characteristic histological evidence of myocardial damage. However, it is not possible to exclude the possibility that minute amounts of nonconfluent myocardial damage (that were not detectable by random sampling and light microscopy) could have led to the release of small amounts of MBCK. This argument cannot be adjudicated definitively at present. However, CK release after rigorous exercise is associated with skeletal muscle necrosis. Similar physiology may exist in myocardium as well. This is consistent with data demonstrating that patients with chest pain and minor increases in MBCK indicative of AMI but without marked elevations in total CK are at increased risk for subsequent cardiac events. 47 
Techniques of Measurement
Assays of CK activity and/or mass can be done on either plasma or serum. Samples should be maximally reduced with f8-mercaptoethanol to protect against oxidation of sulfhydryl groups in the active center, which leads to loss of activity.48 Commercial kits contain reagents to inhibit adenylate kinase, which can be released by red blood cells, resulting in artifactual elevations of CK activity. 49 Assays for total and MBCK activity and mass have been reviewed extensively elsewhere.50'51 Artifacts can occur with any assay but are particularly common with electrophoresis. Naturally fluorescing compounds such as bilirubin, benzodiazipines, antidepressants, pyridoxime, and aspirin in high doses can produce artifactual bands by electrophoresis. Patients with renal failure can also manifest artifactual bands that comigrate with MBCK and BBCK. 44 Carryover of MM into the MB fraction is a common problem with "column" methods,52 and assays that detect B subunits53 can measure elevated levels that are the results of brain injury; pregnancy; carcinoma of the prostate, lung, or gastrointestinal tract; tuberculosis; or uterine abnormalities. Up to 3.2% of hospitalized patients have detectable circulating levels of BBCK.54 Because BB is cleared rapidly, it usually is only detectable in patients with disease processes that result in continuing release.
Assays based on monoclonal antibodies that measure MBCK mass are rapid, highly sensitive and specific, and are now the analytic method of choice.55 However, monoclonal antibodies directed against different epitopes of the same marker may be affected differently by pathological and/or artifactual processes. 26 Recently, it was found that elevations in MBCK mass were produced by cross-reactivity of atypical forms of alkaline phosphatase in plasma with the alkaline phosphatase used to stabilize the reagents for the assay.56 Similar artifactual results can occur with all assays using monoclonal antibodies. In general, mass and activity assays yield comparable results, with the occasional exception of samples with very high total and MBCK values. 57 Macrokinases, including immunoglobulin G bound to BBCK (macro-CK1) or aggregates of mitochondrial CK (macro-CK2), are detected with many assays.58,59 In a prospective study of 3000 hospitalized patients,58 macrokinases were detected in 4.2% (1.0% had type 1 and 3.4% had type 2), but for patients with cardiovascular disease, this may be a substantial overestimation.26 Macro-CK1 migrates close to and is often indistinguishable from MBCK on electrophoretic separations, thus markedly increasing the percentage of MBCK with respect to total CK. Macro-CK1 is detected most often in chronically ill older women. Macro-CK2 migrates near MMCK, resulting in elevations in total CK activity.59 The presence of macro-CK2 is associated with chronic disease (especially liver cirrhosis and malignancy) and severe acute illness. In contrast to free CK enzyme, macrokinases are heat stabile. The persistence of enzyme activity after incubation for 20 minutes at 45°C has been used to verify the presence of macrokinase activity.26 Although it is hoped that the newer assays based on mass will be less affected by macrokinases, cross-reactivity may still occur.
Diagnosis ofAMI
Measurement of MBCK is currently the test of choice to confirm the diagnosis of an AMI."1 (See Table 1 93 Since MMCK isoforms are not specific for myocardium, their utilization for the diagnosis of AMI requires that acute skeletal muscle damage be excluded. Even then, the specificity of MMCK isoforms for the early diagnosis of AMI varies between 77% and 94%, depending on the specific criteria used.92 '93 Measurement of MBCK isoforms could be more specific than MMCK isoforms for the diagnosis of AMI. Because the absolute levels of MBCK in plasma are low (much lower than MMCK), the release of small amounts of the tissue isoform (MB2) will result in a marked change in the ratio of MB2/MB1 hours before elevations of circulating MBCK are manifest. However, it may be that the small amounts of MB2 contained in skeletal muscle could deleteriously affect cardiac specificity by the same mechanism. This issue is yet to be resolved. Application of MB isoforms in patients with a high pretest probability of AMI, as with all such tests, improves the cardiac specificity. The presence of elevated levels of MBCK isoforms, defined as a plasma MB2 activity > 1.0 U/L and a MB2/MB1 ratio > 1.5, has a 59% sensitivity for the diagnosis of AMI at 2 to 4 hours and a 92% sensitivity at 4 to 6 hours after the onset of symptoms. 96 The early accuracy of these criteria may improve if separation of all the isoforms known to circulate in plasma can be accomplished. Myocardial injury that is not due to AMI may also be detectable by analysis of CK isoforms. The proportion of MB2 to total MBCK in plasma has been found to be elevated in patients with cardiac transplant rejection and cardiomyopathy.97'98 Whether this is due to skeletal muscle or cardiac release is unclear at present.
Detection of Reperfusion
The presence of the combination of relief of chest pain, normalization of ST-segment changes, and reperfusion arrhythmias has been found to be indicative of coronary recanalization, but these criteria are not sensitive because all three occur in only 15% of patients.99 Results with CK isoforms have been far more promising (Table 2) .100,101 An accelerated rate of increase of MM3% in plasma reliably distinguishes animals with and without coronary recanalization by 30 LD-1 is the predominant form in heart but also occurs in erythrocytes, brain, pancreas, kidney, and stomach. LD-2 is also abundant in heart; LD-3, LD-4, and LD-5 are found in only trace amounts. All LD isoenzymes are abundant in many tissues, whereas LD-5 is the predominant isoenzyme in skeletal muscle. The specificity of cardiac troponin T (cTnT) for myocardium has not been fully delineated. Skeletal muscle troponin T (sTnT) and cTnT are coexpressed in fetal heart muscle, with the skeletal muscle form being suppressed during ontogeny and reexpressed in stressed human heart.150 ' 
Estimation of Infarct Size
Longer-lived structural protein markers such as the troponins or MLC, whose release ratios are less affected by alterations in blood flow, probably will replace MBCK for this use. However, because of the prolonged release of these markers, blood samples will have to be obtained for an extended period of time for these studies. These techniques require further validation.
